GENELUX Corp

Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.

GNLX | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 2625 TOWNSGATE ROAD, SUITE 230, 91361 WESTLAKE VILLAGE
Website:: https://genelux.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genelux Corporation is a late clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for patients with difficult-to-treat cancers. The company's core technology is a therapeutics and diagnostics platform based on a proprietary, highly customizable vaccinia virus (VACV) backbone. Its lead clinical candidate, Olvi-Vec, is a modified oncolytic vaccinia virus undergoing a registrational Phase 3 trial for platinum-resistant/refractory ovarian cancer. Product development is accelerated by the proprietary CHOICE™ discovery platform, which enables the rapid generation of new viral candidates. Genelux aims to create versatile, "off-the-shelf" immunotherapies with systemic administration potential for a broad range of solid and metastatic tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all GENELUX Corp filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GENELUX Corp

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for GENELUX Corp via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Alpha Cognition Inc. Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.	United States of America	ACOG
Alteogen Inc. Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.	South Korea	196170
ALTERITY THERAPEUTICS LTD Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.	United States of America	ATHE
Alto Neuroscience, Inc. Developing precision medicines for depression and schizophrenia using a brain biomarker platform.	United States of America	ANRO
ALUMIS INC. Develops targeted oral therapies for immune-mediated diseases using precision immunology.	United States of America	ALMS
Alvotech Develops and manufactures affordable biosimilar medicines for patients worldwide.	United States of America	ALVO
Alvotech Holdings S.A Develops and manufactures affordable biosimilar medicines for global patient access.	Luxembourg	ALVO
ALX ONCOLOGY HOLDINGS INC Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.	United States of America	ALXO
Alzamend Neuro, Inc. Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.	United States of America	ALZN
Alzinova AB Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.	Sweden	ALZ